Status:
TERMINATED
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
21+ years
Phase:
NA
Brief Summary
Positron Emission Mammography (PEM) is a newly developed imaging examination of the breast that uses a radioactive glucose based tracer, which is a form of sugar attached to a low radiation agent, to ...
Eligibility Criteria
Inclusion
- Female patients with recently diagnosed invasive or in situ breast cancer by core needle biopsy or FNA (confirmed at MSKCC) prior to enrollment.
- Patients planning treatment with mastectomy at MSKCC.
- Patients 21 years old or older.
- Patients who had or are having a breast MRI within 30 days or less of PEM.
- Patients who had or are having a digital mammogram.
Exclusion
- Patients who are pregnant or breast feeding.
- Patients with prior radiation therapy or endocrine therapy.
- Patients who had a prior lumpectomy.
- Patients who are diabetic.
- Patients with moderate to end stage kidney disease.
- Patients who have a contraindication to MRI (i.e. pacemaker, metallic implants, etc).
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01249157
Start Date
November 1 2010
End Date
August 1 2012
Last Update
December 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065